>
pdufa.bio

Tislelizumab

Updated ยทnext FDA decision on the calendar

Tislelizumab is a Takeda Pharmaceutical Co Ltd program. Its next catalyst is a Readout in Dec 2027. Every date links its source.

TAK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Takeda Pharmaceutical Co Ltd (TAK). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2027TAK

Questions

When is Tislelizumab's next FDA decision or readout?

The next tracked catalyst for Tislelizumab is a Readout in Dec 2027.

What happened at Tislelizumab's most recent FDA decision?

No FDA decision for Tislelizumab is in our archive yet.

Who makes Tislelizumab?

Takeda Pharmaceutical Co Ltd (TAK).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.